Literature DB >> 3782818

Studies on the detrimental effects of bivalent binding in a microtitration plate ELISA and possible remedies.

H A Kemp, M R Morgan.   

Abstract

During the development of a microtitration plate enzyme-linked immunosorbent assay (ELISA) for 3-acetyldeoxynivalenol, using an immobilised hapten:protein conjugate, problems were encountered in obtaining an inhibition curve with hapten. Investigations into this phenomenon were conducted. Univalent Fab fragments were prepared and their binding compared with untreated antiserum on plates coated with different immobilised coating concentrations and with conjugate of a lower hapten:protein ratio. The studies showed that standard curves obtained with Fab fragments using the coating conjugate of high hapten ratio were more sensitive and showed a greater degree of inhibition. However with the conjugate of lower hapten ratio the untreated antiserum gave the more sensitive curve although inhibition was incomplete. From these results it is concluded that the antiserum probably contains two populations of antibodies, one of which binds bivalently to the plates at all concentrations of immobilised hapten.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3782818     DOI: 10.1016/0022-1759(86)90216-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

1.  Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates.

Authors:  A F Verheul; G J Boons; G A Van der Marel; J H Van Boom; H J Jennings; H Snippe; J Verhoef; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

2.  Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins.

Authors:  X X Gu; C M Tsai; T Ueyama; S J Barenkamp; J B Robbins; D J Lim
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

3.  Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.

Authors:  X X Gu; J Chen; S J Barenkamp; J B Robbins; C M Tsai; D J Lim; J Battey
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

4.  Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.

Authors:  A F Verheul; A K Braat; J M Leenhouts; P Hoogerhout; J T Poolman; H Snippe; J Verhoef
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

6.  Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.

Authors:  X X Gu; C M Tsai
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

7.  Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates.

Authors:  A F Verheul; A A Versteeg; M J De Reuver; M Jansze; H Snippe
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

8.  Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.

Authors:  A F Verheul; J A Van Gaans; E J Wiertz; H Snippe; J Verhoef; J T Poolman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

9.  Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines.

Authors:  E A de Velasco; D Merkus; S Anderton; A F Verheul; E F Lizzio; R Van der Zee; W Van Eden; T Hoffman; J Verhoef; H Snippe
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.